Dey Adwitia, Allen Joselyn, Hankey-Giblin Pamela A
Department of Veterinary and Biomedical Sciences, The Pennsylvania State University , University Park, PA , USA ; Graduate Program in Physiology, The Pennsylvania State University , University Park, PA , USA.
Department of Veterinary and Biomedical Sciences, The Pennsylvania State University , University Park, PA , USA ; Graduate Program in Immunology and Infectious Disease, The Pennsylvania State University , University Park, PA , USA.
Front Immunol. 2015 Jan 22;5:683. doi: 10.3389/fimmu.2014.00683. eCollection 2014.
The explosion of new information in recent years on the origin of macrophages in the steady-state and in the context of inflammation has opened up numerous new avenues of investigation and possibilities for therapeutic intervention. In contrast to the classical model of macrophage development, it is clear that tissue-resident macrophages can develop from yolk sac-derived erythro-myeloid progenitors, fetal liver progenitors, and bone marrow-derived monocytes. Under both homeostatic conditions and in response to pathophysiological insult, the contribution of these distinct sources of macrophages varies significantly between tissues. Furthermore, while all of these populations of macrophages appear to be capable of adopting the polarized M1/M2 phenotypes, their respective contribution to inflammation, resolution of inflammation, and tissue repair remains poorly understood and is likely to be tissue- and disease-dependent. A better understanding of the ontology and polarization capacity of macrophages in homeostasis and disease will be essential for the development of novel therapies that target the inherent plasticity of macrophages in the treatment of acute and chronic inflammatory disease.
近年来,关于稳态和炎症背景下巨噬细胞起源的新信息激增,开辟了众多新的研究途径和治疗干预的可能性。与经典的巨噬细胞发育模型不同,很明显组织驻留巨噬细胞可源自卵黄囊衍生的红系髓系祖细胞、胎儿肝脏祖细胞以及骨髓来源的单核细胞。在稳态条件下以及对病理生理损伤作出反应时,这些不同来源的巨噬细胞在不同组织中的贡献差异显著。此外,虽然所有这些巨噬细胞群体似乎都能够呈现极化的M1/M2表型,但其对炎症、炎症消退和组织修复的各自贡献仍知之甚少,并且可能取决于组织和疾病。更好地理解稳态和疾病中巨噬细胞的本体论和极化能力,对于开发针对巨噬细胞固有可塑性以治疗急慢性炎症性疾病的新疗法至关重要。